50980 Federal Register / Vol. 74, No. 190 / Friday, October 2, 2009 / Notices 

November 19, 2009 

National Institute of Environmental 

Health Sciences 

Rodbell Auditorium, Rall Building 

111 T.W. Alexander Drive, Research 

Triangle Park, NC 

Technical Reports (TR) Scheduled for 

Review 

• TR 564 1–Bromopropane (CASRN 

106–94–5) 

Æ Previously used as an intermediate 

in the production of pesticides, 

quaternary ammonium compounds, 

flavors, and fragrances. Introduced 

as a less toxic replacement for 

methylene chloride in emissive 

applications such as vapor and 

immersion degreasing operations 

and critical cleaning of electronics 

and metals. Used as a relatively 

nonflammable, nontoxic, fastdrying, and inexpensive solvent for 

adhesive resins, and as a 

replacement for ozone-depleting 

refrigerants. 

• TR 565 Milk Thistle Extract (CASRN 

84604–20–6) 

Æ Milk thistle extracts are used as 

herbal medicines to treat a variety 

of diseases (e.g., liver disease) and 

as a food additive. 

• TR 566 Diethylamine (CASRN 109– 

89–7) 

Æ Used mainly as a chemical 

intermediate to produce the 

corrosion inhibitor, N,Ndiethylethanolamine, and to lesser 

extent to produce pesticides, insect 

repellants, pharmaceuticals, and 

rubber processing chemicals. 

• TR 567 Ginseng (CASRN 50647–08–0) 

Æ Ginseng is a perennial aromatic 

herb widely used in herbal 

remedies for enhancing stamina and 

endurance for mental and physical 

performance. 

• TR 563 Pulegone (CASRN 89–82–7) 

Æ Several essential oils that contain 

pulegone are used for flavoring 

foods, drinks, and dental products, 

as fragrance agents, and in herbal 

medicines. 

• TR 536 Bis(2-chloroethoxy) methane 

(CASRN 111–91–1) 

Æ Used as a solvent and as the 

starting agent in the production of 

fungicides and polysulfide 

polymers. 

[FR Doc. E9–23781 Filed 10–1–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Oncologic Drugs Advisory Committee; 

Cancellation 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The meeting of the Oncologic 

Drugs Advisory Committee scheduled 

for October 6, 2009, is cancelled. This 

meeting was announced in the Federal 

Register of August 25, 2009 (74 FR 

42907). The October 6, 2009, Oncologic 

Drugs Advisory Committee meeting was 

to discuss ApoPharma, Inc.’s new drug 

application (NDA) 021–825 for 

proposed trade name FERRIPROX 

(deferiprone) film-coated tablets. This 

meeting has been cancelled to allow 

time for FDA to review and resolve 

several outstanding issues. The agency 

intends to continue evaluating NDA 

021–825 and, as needed, may schedule 

an advisory committee meeting in the 

future. 

FOR FURTHER INFORMATION CONTACT: 

Nicole Vesely, Center for Drug 

Evaluation and Research (HFD–21), 

Food and Drug Administration, 5600 

Fishers Lane (for express delivery, 5630 

Fishers Lane, rm. 1093), Rockville, MD 

20857, 301–827–6793, FAX: 301–827– 

6776, e-mail: nicole.vesely@fda.hhs.gov, 

or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington, DC 

area), code 3014512542. Please call the 

Information Line for up-to-date 

information on this meeting. 

Dated: September 28, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–23764 Filed 10–1–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Special 

Conflict. 

Date: October 15, 2009. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Avenue, NW., Washington, DC 20037. 

Contact Person: Russell T. Dowell, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4128, 

MSC 7814, Bethesda, MD 20892. (301) 435– 

1850. dowellr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Psychopathology and Adult Disorders. 

Date: October 29, 2009. 

Time: 8 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Parc 55 Hotel, 55 Cyril Magnin 

Street, Market at Fifth, San Francisco, CA 

94102. 

Contact Person: Biao Tian, PhD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3089B, MSC 7848, Bethesda, 

MD 20892. (301) 402–4411. 

tianbi@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Technological Innovations for 

Interdisciplinary Research. 

Date: October 29, 2009. 

Time: 3 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Parc 55 Hotel, 55 Cyril Magnin 

Street, Market at Fifth, San Francisco, CA 

94102. 

Contact Person: Biao Tian, PhD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3089B, MSC 7848, Bethesda, 

MD 20892. (301) 402–4411. 

tianbi@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Science 

Education, Communication and Childhood 

Disorders. 

Date: October 30, 2009. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Parc 55 Hotel, 55 Cyril Magnin 

Street, Market at Fifth, San Francisco, CA 

94102. 

Contact Person: Biao Tian, PhD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 


pwalker on DSK8KYBLC1PROD with NOTICES
Federal Register / Vol. 74, No. 190 / Friday, October 2, 2009 / Notices 50981 

Drive, Room 3089B, MSC 7848, Bethesda, 

MD 20892. (301) 402–4411. 

tianbi@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 25, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23719 Filed 10–1–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Meeting of the AHRQ National 

Advisory Council for Healthcare 

Research and Quality Subcommittee 

on Patient Safety and Medical Liability 

Reform Demonstrations 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of public meeting. 

SUMMARY: This notice announces a 

meeting of the National Advisory 

Council for Healthcare Research and 

Quality Subcommittee on Patient Safety 

and Medical Liability Reform 

Demonstrations. 

DATES: The meeting will be held in 

October; specific information will be 

available on the AHRQ Web site at 

http://www.AHRQ.gov. 

ADDRESSES: To be determined; in 

Washington, DC Metro area; specific 

information will be available at http:// 

www.AHRQ.gov. 

FOR FURTHER INFORMATION CONTACT: 

Christine Williams, Director for 

Strategic Partnerships, Agency for 

Healthcare Research and Quality, 540 

Gaither Road, Rockville, Maryland 

20850, (301) 427–1850. 

For press-related information, please 

contact: Karen Migdail at (301) 427– 

1855. 

If sign language interpretation or 

other reasonable accommodation for a 

disability is needed, please contact: Mr. 

Michael Chew, Director, Office of Equal 

Employment Opportunity Program, 

Program Support Center, (301) 443– 

1144 (no later than October 15, 2009). 

SUPPLEMENTARY INFORMATION: 

I. Purpose 

The National Advisory Council for 

Healthcare Research and Quality was 

established in accordance with Section 

921 (now Section 931) of the Public 

Health Service Act, 42 U.S.C. 299c. In 

accordance with its statutory mandate, 

the Council is to advise the Secretary of 

the Department of Health and Human 

Services and the Director, Agency for 

Healthcare Research and Quality 

(AHRQ), on matters related to actions of 

AHRQ to enhance the quality, and 

improve the outcomes, of health care 

services; improve access to such 

services through scientific research; and 

promote improvements in clinical 

practice and in the organization, 

financing, and delivery of health care 

services. 

The Council is composed of members 

of the public, appointed by the 

Secretary, and Federal ex-officio 

members. AHRQ’s National Advisory 

Council on Healthcare Research and 

Quality (NAC) will establish a 

Subcommittee on Patient Safety and 

Medical Liability Reform 

Demonstrations. 

The Subcommittee will be created to 

provide advice to the NAC for 

consideration and transmission to 

AHRQ as AHRQ undertakes the 

development of a new demonstration 

initiative that will help States and 

health care systems to test models that 

put patient safety first and work to 

reduce preventable injuries, foster better 

communication between doctors and 

their patients, ensure that patients are 

compensated in a fair and timely 

manner for medical injuries, while 

reducing the incidence of frivolous 

lawsuits; and reduce liability premiums. 

As directed by President Obama, the 

Secretary of the Department of Health 

and Human Services (HHS) will launch 

a competitive three-pronged initiative 

that will include support for 

demonstration grants to States and 

health systems, planning grants to States 

and health systems, and a rapid and 

comprehensive review of current efforts, 

targeting patient safety and medical 

liability. Prior to finalizing the Funding 

Opportunity Announcement for this 

new initiative, the chairman of AHRQ’s 

National Advisory Council will convene 

a subcommittee with diverse 

representation from expert and 

stakeholder groups to provide advice for 

this initiative. The date, time, location 

and agenda for the subcommittee 

meeting, which will be open to the 

public, will be available on the AHRQ 

Web site no later than two weeks in 

advance of such meeting. Members of 

the public will have the opportunity to 

submit comments to the subcommittee 

in person or in writing, and can 

participate in the meeting in person or 

via Web casting. The subcommittee will 

not review individual grants nor 

participate in award decisions. 

A roster of the Subcommittee 

members will be available at http:// 

www.AHRQ.gov. 

A more specific proposed agenda will 

be available before the meeting at http://

www.AHRQ.gov. 

The final agenda, including the time 

for public comment during the meeting, 

will be available on the AHRQ Web site 

at http://www.AHRQ.gov. Public 

comments may also be submitted in 

writing by e-mail, fax, mail, or hand 

delivery. E-mails are preferred. Please 

submit comments to: 

Medicalliabilitydemos@AHRQ.hhs.gov. 

A comment submitted by e-mail should 

indicate that it is in response to 

‘‘Medical Liability Reform 

Demonstrations Subcommittee.’’ The 

deadline for written comments will be 

posted on the AHRQ Web site. Meeting 

minutes will be available within 21 

business days after the meeting. 

Dated: September 24, 2009. 

Carolyn M. Clancy, 

Director. 

[FR Doc. E9–23594 Filed 10–1–09; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Indian Health Service 

Privacy Act of 1974; Report of an 

Altered System of Records; Medical 

Staff Credentials and Privileges 

Records 

ACTION: Notice; correction. 

SUMMARY: The Indian Health Service 

published a document in the Federal 

Register (FR) on September 9, 2009. The 

document contained three errors. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Betty Gould, Regulations Officer, 801 

Thompson Avenue, TMP, Suite 450, 

Rockville, MD 20852, Telephone (301) 

443–7899. (This is not a toll-free 

number.) 

Correction 

In the Federal Register of September 

9, 2009 in FR Doc. E9–21422, on page 

46437, in the third column, tenth line, 

change IRS to IHS; on page 46438, in the 

first column, second line, change HH to 

HHS; and on page 46439, in the first 

column, 25th line Records Source 

Categories, change IRS to IHS. 


pwalker on DSK8KYBLC1PROD with NOTICES